AP
VRTX icon

Arlington Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Arlington Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-34
Closed -$11.8K – 395
2023
Q3 		$11.8K Hold
34
– – ﹤0.01% 220
2023
Q2 		$12K Sell
34
-66
-66% -$22.2K ﹤0.01% 447
2023
Q1 		$31.5K Buy
+100
New +$30K ﹤0.01% 299
2022
Q1 		– Sell
-49
Closed -$11K – 658
2021
Q4 		$11K Buy
+49
New +$9.53K ﹤0.01% 461
2020
Q2 		– Sell
-46
Closed -$11K – 289
2020
Q1 		$11K Hold
46
– – 0.01% 163
2019
Q4 		$10K Buy
+46
New +$9.31K 0.01% 197
2019
Q1 		– Sell
-46
Closed -$8K – 240
2018
Q4 		$8K Buy
+46
New +$7.97K 0.01% 174

Other funds holding VRTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return